Renalytix AI

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Renalytix AI sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials 2 currently recruiting upper quartile by trial count

Renalytix AI: 4 sponsored US clinical trials, 2 recruiting.

Renalytix AI sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. The most-studied condition in this pipeline is Diabetic Kidney Disease, with 4 trials.

Upper-quartile sponsor footprint

Renalytix AI sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

What is open in the Renalytix AI pipeline

2 recruiting of 4 indexed (50% open).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Diabetic Kidney Disease (4 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Renalytix AI: open-pipeline peers nationwide

Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Renalytix AI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60%80% Total trials Recruiting share Renalytix AI4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action Lab1200 Pharma1ST Biotherapeutics3ive Labs7 Hills Pharma
Renalytix AI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Renalytix AI sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Renalytix AI page

4 registered trials is a research-attention snapshot, not an endorsement of Renalytix AI or any single study.

  • 2 of Renalytix AI's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Diabetic Kidney Disease is the condition Renalytix AI studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Diabetic Kidney Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Renalytix AI pipeline card: 4 registered trials from official public datasets.Report a data error.